NEW YORK (360Dx) – Biodesix last month presented data on a proteomic test for predicting lung cancer patients' response to nivolumab (marketed by Bristol-Myers Squibb as Opdivo), as the company continues its efforts in immune-oncology.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.